Valsartan superior amlodipine in the protection of patients have moderate hypertension with cardiovascular risks in Najaf province.
- Department of of Laboratory Investigation, Faculty of Sciences, Kufa University, AL-Najef, 54001, Iraq.
- Abstract
- Cite This Article as
- Corresponding Author
This study was between 2/04/2015 to 1/05/2015 to know the best drug to moderate hypertension patients. The data were obtained from the Al_Sadar and Al_Hakeem hospitals. The diagnosis of moderate hypertension (140 to 159 SBP) patients was depended on internal physicians were employees in mentioned hospitals. The data collection from moderate hypertension (n=35) received valsartan (Diovan 80 mg) and other group (n=35) received amlodipine 5 mg. The healthy group (n=20) was health people don't have hypertension and other cardiovascular risks. This study explained that patients received valsartan 80 mg have efficacy and better in protection from recurrent cardiovascular risks (angina and stroke). Also our study clear up that same group have less number in heart failure occurred.
[Majeed A.A, Lina A. Hassan, Kawther Aljanabi and Alyaa Alfadly (2016); Valsartan superior amlodipine in the protection of patients have moderate hypertension with cardiovascular risks in Najaf province. Int. J. of Adv. Res. 4 (Feb). 31-37] (ISSN 2320-5407). www.journalijar.com
